Magnesium: What the Evidence Says

Quick Answer

Magnesium has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Disturbance in magnesium levels has been associated with insulin resistance, endothelial dysfunction, and increased oxidative stress in the background of type 2 diabetes mellitus. [Kubbara Eman A. (2026); evidence level 1]
• Therefore, reduced magnesium levels may permit excessive intracellular calcium and sodium influx, leading to excitotoxic neuronal damage that contributes to diabetic retinopathy. [Kubbara Eman A. (2026); evidence level 1]
• Thus, this review aims to integrate advances in magnesium physiology with contemporary clinical and nutritional evidence, providing a consolidated strategy for understanding the causes, manifestations, diagnosis, and management of hypomagnesemia. [Papagiannidou Anastasia (2026); evidence level 3]
• Finally, we also cover practical laboratory assessment and evidence-informed repletion strategies. [Papagiannidou Anastasia (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For magnesium, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Bottom Line For Readers

For magnesium, this knowledge-base sample includes at least one stronger evidence source. One representative source-reported claim is: "Disturbance in magnesium levels has been associated with insulin resistance, endothelial dysfunction, and increased oxidative stress in the background of type 2 diabetes mellitus." The safest editorial posture is to separate general magnesium physiology from claims about specific outcomes, forms, or doses.

Evidence Strength

The current evidence set includes 2 unique source documents. 1 source is level 1-2 in this system, while 1 source is lower-level, indirect, narrative, or early-stage evidence. Treat this as a structured reading guide rather than a final clinical guideline.

What This Means In Practice

• Separate dietary magnesium, supplemental magnesium, and medical hypomagnesemia.
• Avoid implying that every magnesium form has the same absorption, tolerance, or use case.
• Flag kidney disease, medication interactions, pregnancy, and high-dose supplementation as clinician-discussion contexts.

What The Evidence Does Not Prove

• It does not prove that magnesium supplementation improves sleep, anxiety, cramps, or glucose control for every reader.
• It does not prove that one supplement form is always superior without form-specific comparative evidence.

Editorial Use Cases

This page is most useful as a citation hub for answer-first pages about magnesium. It can support cautious explainers, comparison sections, safety notes, and evidence tables. It should not be used alone to rank products, promise outcomes, or replace condition-specific clinical guidance.

Limits Of This First Pass

This deep evidence page is still generated from a bounded knowledge-base sample. It should be reviewed by a human editor before being used for high-stakes decisions or product-ranking claims.

References

• Kubbara Eman A. (2026). Association Between Levels of Magnesium and Diabetic Retinopathy in Diabetic Patients with Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-Analysis. DOI: 10.3390/nu18071162. PMCID: PMC13074579. PMID: 41978212. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13074579/
• Papagiannidou Anastasia (2026). Hypomagnesemia: A Clinical and Nutritional Update. DOI: 10.1007/s13668-026-00745-5. PMCID: PMC13009017. PMID: 41872423. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13009017/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.